Royalty Pharma
110 East 59th Street
33rd Floor
New York
New York
10022
United States
Tel: (212)-883-0200
Fax: (212) 883-2260
Website: http://www.royaltypharma.com/
Email: info@royaltypharma.com
71 articles with Royalty Pharma
-
Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness
1/9/2023
Ionis Pharmaceuticals, Inc. and Royalty Pharma plc announced that Royalty Pharma has acquired an interest in Ionis' royalty in Biogen's SPINRAZA® and Novartis' pelacarsen for up to $1.125 billion, including an upfront payment of $500 million and up to $625 million in additional pelacarsen milestone payments.
-
Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
11/9/2022
Arrowhead Pharmaceuticals Inc. and Royalty Pharma plc announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead for $250 million in cash upfront plus up to $160 million in additional payments contingent on the achievement of certain clinical, regulatory, and sales milestones.
-
Under the terms of the deal, Theravance and Innoviva are surrendering 85% and 15% of their stakes in Trelegy in exchange for $1.1 billion and $282 million from Royalty, respectively.
-
Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 million milestone payment
7/13/2022
Innoviva, Inc. announced that the company has entered into an agreement to sell its 15% economic stake in Theravance Respiratory Company LLC, which receives royalties stemming from sales of TRELEGY® ELLIPTA®, to Royalty Pharma plc for an upfront cash payment of approximately $282 million and a potential $50 million contingent sales-based milestone payment.
-
Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value
7/13/2022
Theravance Biopharma, Inc. announced it has entered into a definitive agreement to sell all of its units in Theravance Respiratory Company, LLC representing its 85% economic interest in the sales-based royalty rights on worldwide net sales of GSK's TRELEGY ELLIPTA to Royalty Pharma for over $1.5 billion in potential total value.
-
Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million
1/7/2022
Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten Royalty Pharma Purchases Royalties on Future Sales of Aficamten.
-
Mark Charest, Ph.D., of LifeSci Fund Management, said the J.P. Morgan Healthcare Conference will set the tone for biotech stock performance in 1H 2022.
-
BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets
11/22/2021
BioCryst Pharmaceuticals, Inc., Royalty Pharma plc and OMERS Capital Markets, announced transactions totaling $350 million in new funding for BioCryst, with all funds immediately available at closing.
-
This week, Berkshire announced that it has scaled back those investments, and completely eliminated its stake in Merck.
-
MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma
6/2/2021
MorphoSys AG (FSE:MOR) announces today that it has entered into a definitive agreement with Constellation Pharmaceuticals, Inc. (NASDAQ: CNST) whereby MorphoSys will acquire Constellation for $34.00 per share in cash, which represents a total equity value of $1.7 billion.
-
MorphoSys Pharma's Double Deal: Buys Constellation and Enters Partnership with Royalty Pharma
6/2/2021
MorphoSys Pharma is acquiring Constellation Pharmaceuticals for about $1.7 billion. Here's everything you need to know about this billion dollars deal. -
MSCI Announces Strategic Alliance With Royalty Pharma to Launch Life Sciences Indexes
4/21/2021
MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today its collaboration with Royalty Pharma plc (Nasdaq: RPRX), the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, to expand MSCI’s thematic index suite with the launch of new indexes
-
Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million
4/8/2021
– Dicerna To Receive $180 Million Upfront and Up to $60 Million in Potential Additional Milestone Payments
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 22, 2020.
-
New Ventures Funds Rebrands as Scientia Ventures
10/2/2020
New Ventures Funds has launched a new corporate brand identity and changed its name to Scientia Ventures. The new website for the firm can be found at: www.scientiavc.com.
-
Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million
8/7/2020
- Biohaven will receive up to $250 million to fund zavegepant's development in migraine and non-migraine indications - Royalty Pharma to acquire up to a 3% royalty for zavegepant, a 0.4% royalty of Nurtec™ ODT and success-based milestone payments - Royalty Pharma will purchase new Commercial Launch Preferred Equity from Biohaven for a total of $200 million payable between 2021 and 2024, providing additional funding for its CGRP-targeting franchise
-
New Ventures Portfolio Company, Royalty Pharma, Surges On Public Debut
6/25/2020
New Ventures Funds , a venture fund targeting investments in companies across healthcare and life sciences, is pleased to announce the IPO of one of its portfolio companies, Royalty Pharma (NASDAQ:RPRX). The company raised $2.18 billion through the sale of 77,681,670 of its Class A ordinary shares priced at $28.00 per share
-
Agios and Royalty Pharma Announce $255 Million Purchase Agreement for IDHIFA® Royalty
6/12/2020
Royalty Pharma Acquires Rights to Agios’ Royalty on IDHIFA® Worldwide Net Sales and Outstanding Regulatory Milestone Payments
-
In a regulatory filing, Royalty Pharma indicated plans to offer 70 million shares of stock at a target price range of $25 to $28 per share, which would result in raising up to $1.96 billion for its initial public offering.
-
Royalty Pharma Acquires Royalties on Entyvio® from Massachusetts General Hospital
3/5/2020
Royalty Pharma announced that it has acquired Massachusetts General Hospital's royalty interest in Entyvio for $94 million.